Prospects for Treatment of Pediatric Vitreoretinal Diseases with Vascular Endothelial Growth Factor Inhibition

REFERENCES

• Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: Roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci 2000; 41: 1217–1228
   PubMed Web of Science ®Google Scholar
• Bhisitkul R B. Vascular endothelial growth factor biology: Clinical implications for ocular treatments. Br J Ophthalmol 2006; 90: 1542–1547
   PubMed Web of Science ®Google Scholar
• Gordon J D, Mesiano S, Zaloudek C J, Jaffe R B. Vascular endothelial growth factor localization in human ovary and fallopian tubes: Possible role in reproductive function and ovarian cyst formation. J Clin Endocrinol Metab 1996; 81: 353–359
   PubMed Web of Science ®Google Scholar
• Senger D R, Galli S J, Dvorak A M, Perruzzi C A, Harvey V S, Dvorak H F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983–985
   PubMed Web of Science ®Google Scholar
• Leung D W, Cachianes G, Kuang W J, Goeddel D V, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306–1309
   PubMed Web of Science ®Google Scholar
• Bates D O, Harper S J. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 2002; 39: 225–237
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber H P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669–676
   PubMed Web of Science ®Google Scholar
• Kelly B D, Hackett S F, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, Rowan A, Yan Z, Campochiaro P A, Semenza G L. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 2003; 93: 1074–1081
   PubMed Web of Science ®Google Scholar
• Vinores S A, Youssri A L, Luna J D. Upregulation of vascular endothelial growth factor in ischemic and no-ischemic human and experimental retinal disease. Histol Histopathol 1997; 12: 99–109
   PubMed Web of Science ®Google Scholar
• Bates D O, Harper S J. Therapeutic potential of inhibitory VEGF splice variants. Future Oncol 2005; 1: 467–73
   PubMedGoogle Scholar
• Palmer E A, Phelps D L, Spencer R, Lutty G A. Retinopathy of prematurity. Retina, S Ryan. Elsevier-Mosby, Philadelphia, PA 2006; 1447–1474
   Google Scholar
• Penn J S, Tolman B L, Lowery L A. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthalmol Vis Sci 1993; 34: 576–585
   PubMed Web of Science ®Google Scholar
• Gu X, El-Remessy A B, Brooks S E, Al-Shabrawey M, Tsai N T, Caldwell R B. Hyperoxia induces retinal vascular endothelial cell apoptosis through formation of peroxynitrite. Am J Physiol Cell Physiol 2003; 285: 546–554
   PubMed Web of Science ®Google Scholar
• Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 1: 1024–1028
   PubMed Web of Science ®Google Scholar
• Pierce E A, Foley E D, Smith L E. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996; 114: 1219–1228
   PubMedGoogle Scholar
• Lashkari K, Hirose T, Yazdany J, McMeel J W, Kazlauskas A, Rahimi N. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol 2000; 156: 1337–1344
   PubMed Web of Science ®Google Scholar
• Sonmez K, Drenser K A, Capone A, Jr, Trese M T. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 2008; 115: 1065–1070
   PubMed Web of Science ®Google Scholar
• Quiroz-Mercado H, Martinez-Castellanos M, Hernandez-Rojas M, Salazar-Teran N, Chan P. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina 2008; 28: S19–S25
   PubMed Web of Science ®Google Scholar
• Mintz-Hittner H A, Kuffel R R, Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina Jun, 2008; 28(6)831–838
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435–439
   PubMed Web of Science ®Google Scholar
• Kong L, Mintz-Hittner H A, Penland R L, Kretzer F L, Chévez-Barrios P. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: A morphologic study. Arch Ophthalmol 2008; 126: 1161–1163
   PubMedGoogle Scholar
• Bakri S J, Snyder M R, Reid J M, Pulido J S, Singh R J. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855–859
   PubMed Web of Science ®Google Scholar
• Konopatskaya O, Churchill A J, Harper S J, Bates D O, Gardiner T A. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol Vis 2006; 12: 626–632
   PubMed Web of Science ®Google Scholar
• Quiram P A, Drenser K A, Lai M M, Capone A, Trese M T. Treatment of vascularly active familial exudative vitreoretinopathy with pegaptanib sodium (Macugen). Retina 2008; 28: S8–S12
   Google Scholar
• Criswick V G, Schepens C L. Familial exudative vitreoretinopathy. Am J Ophthalmol 1969; 68: 578–594
   PubMed Web of Science ®Google Scholar
• Zhou S, Overbeek P A. Elevated TGF beta signaling inhibited ocular vascular development. Dev Biol 2001; 237: 45–53
   Google Scholar
• Parmalee N L, Kitajewski J. Wnt signaling in angiogenesis. Curr Drug Targets Jul, 2008; 9(7)558–564
   Google Scholar
• Zerlin M, Julius M A, Kitajewski J. Wnt/Frizzled signaling in angiogenesis. Angiogenesis 2008; 11: 63–69
   PubMed Web of Science ®Google Scholar
• Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1061–1063
   PubMed Web of Science ®Google Scholar
• Tagami M, Kusuhara S, Honda S, Tsukahara Y, Negi A. Rapid regression of retinal hemorrhage and neovascularization in a case of familial exudative vitreoretinopathy treated with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008; 246: 1787–1789
   Google Scholar
• Do D, Haller J. Coats disease. Retina, S Ryan. Elsevier-Mosby, Philadelphia, PA 2006; 1417–1423
   Google Scholar
• Quiroz-Mercado H, Ustariz-González O, Martinez-Castellanos M A, Covarrubias P, Dominguez F, Sanchez-Huerta V. Our experience after 1765 intravitreal injections of bevacizumab: The importance of being part of a developing story. Semin Ophthalmol Apr-Jun, 2007; 22(2)109–125
   PubMedGoogle Scholar
• Jun J H, Kim Y C, Kim K S. Resolution of severe macular edema in adult coats' disease with intravitreal triamcinolone and bevacizumab injection. Korean J Ophthalmol 2008; 22: 190–193
   Google Scholar
• Cakir M, Cekiç O, Yilmaz O F. Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats disease. J AAPOS 2008; 12: 309–311
   Google Scholar
• Meir P, Wiedermann P. Surgical aspects of vitreoretinal diseases in children. Retina., S Ryan. Elsevier-Mosby, Philadelphia, PA 2006; 2494–2495
   Google Scholar
• Saint-Geniez M, Maharaj A S, Walshe T E, Tucker B A, Sekiyama E, Kurihara T, Darland D C, Young M J, D'Amore P A. Endogenous VEGF is required for visual function: Evidence for a survival role on müller cells and photoreceptors. PLoS ONE 2008; 3(11)e3554
   PubMed Web of Science ®Google Scholar